Prof. Dr. Angela Genge Joins AL-S Pharma as Chief Medical Officer
AL-S Pharma is thrilled to announce the appointment of the highly esteemed Prof. Dr. Angela Genge as its Chief Medical Officer (CMO). With a notable career dedicated to neurology, Dr. Genge is widely acknowledged for her extensive research in amyotrophic lateral sclerosis (ALS) and her role as the Head of the ALS Global Centre of Excellence for Research and Patient Care.
Expertise in ALS Research and Development
Dr. Genge comes to this pivotal role with a rich background as a global principal investigator for clinical studies surrounding AP-101, an investigational first-in-class antibody designed to target misfolded SOD1, a key factor in ALS progression. Her leadership in these trials aligns perfectly with AL-S Pharma’s mission to advance novel therapies for ALS patients.
According to Michael Salzmann, CEO of AL-S Pharma, "We are delighted to have Prof. Dr. Genge onboard during this transformative period for our company. Her unparalleled expertise in ALS will be instrumental in propelling our AP-101 program through late-stage development. Together, we strive to develop a groundbreaking therapy that could change the landscape of ALS treatment for many patients."
A Legacy of Innovation and Collaboration
With a remarkable portfolio of achievements, Dr. Genge’s contributions to ALS clinical research are well recognized. Her role as a pivotal investigator on many significant ALS trials and her advisory positions with regulatory authorities and numerous clinical advisory boards demonstrate her deep commitment to advancing ALS research.
In her own words, Dr. Genge expressed her enthusiasm for joining AL-S Pharma: "The company’s dedication to developing AP-101 as an innovative therapy addressing misfolded SOD1 truly inspires me. I eagerly anticipate collaborating with the leadership team to drive this clinical advancement and bring hope to ALS patients around the world."
AP-101: A Promising Advancements in ALS Treatment
AP-101 is an investigational human antibody specifically designed to counteract the misfolded superoxide dismutase 1 (SOD1). This innovative treatment was birthed through Neurimmune’s Reverse Translational Medicine technology, crafted to halt the spread of SOD1-related pathology in the central nervous system of ALS patients.
The Phase 2 study reported by AL-S Pharma meticulously evaluated the safety and efficacy of AP-101, including pharmacodynamic markers and pharmacokinetics in both sporadic and mutant SOD1-ALS patients.
AL-S Pharma: Committed to Neurodegenerative Research
Founded in collaboration with Neurimmune and TVM Capital Life Science, AL-S Pharma is dedicated to delivering innovative therapies for neurological conditions. The company is backed by seasoned professionals in the field, ensuring robust leadership steering the advancement of AP-101.
AL-S Pharma partners with a network of ALS specialists from around the globe to conduct clinical research that can significantly benefit patients suffering from ALS. Their proactive strategies bring together diverse expertise, ensuring they remain at the forefront of treatment development.
Frequently Asked Questions
What is AL-S Pharma's primary focus?
AL-S Pharma specializes in developing innovative treatments for ALS, particularly focusing on its investigational therapy AP-101 aimed at targeting misfolded SOD1.
Who is Prof. Dr. Angela Genge?
Prof. Dr. Angela Genge is a leading neurologist with extensive experience in ALS research, now appointed as AL-S Pharma’s Chief Medical Officer.
What does the AP-101 therapy aim to achieve?
AP-101 is designed to inhibit the progression of neurological damage caused by misfolded SOD1 in ALS patients, offering hope for a disease-modifying treatment.
How is AL-S Pharma funded?
AL-S Pharma is co-owned by Neurimmune and TVM Capital Life Science, fully financing its operations to advance AP-101 research and development in ALS.
Where can I find more information about AL-S Pharma?
For additional details, you can visit AL-S Pharma's official channels, which provide updates on their research and initiatives in ALS treatment.
